AtriCure, Inc. (ATRC)

Over the past six months, AtriCure's stock has experienced several events and movements. Q3 2025 earnings were reported on October 29, 2025, with an EPS of -0.010 USD. Q4 2025 earnings were reported on February 17, 2026, with the company reporting $0.06 EPS for the quarter, beating the consensus estimate of ($0.04), and revenue of $140.50 million, an increase of 13.1% year-over-year. The stock's 52-week range has been between $27.26 and $43.18, and as of early April 2026, the stock has been trading near its 52-week low. Analysts have conflicting sentiments, with a consensus rating of "Moderate Buy" and an average target price of $48.43. An insider, Vinayak Doraiswamy, sold 5,000 shares of the company's stock on March 12, 2026, for a total transaction of $149,150.00.

The provided information does not explicitly detail demand seasonality for AtriCure's products and services, but it highlights strong underlying growth drivers. The company has seen expanding adoption of its pain management, open ablation, and appendage management product lines. The market for AtriCure's products is highly favorable for growth due to strong demographic trends, such as an aging global population, which is increasing the prevalence of conditions like atrial fibrillation. The global market for Afib treatment devices is projected to grow at a Compound Annual Growth Rate (CAGR) of over 13%, indicating a consistent and increasing demand rather than significant seasonality.

AtriCure, Inc. is a medical device company specializing in surgical treatments and technologies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management. The company's mission is to provide innovative surgical solutions to restore normal heart rhythms for Afib patients and manage pain. Major products include the Isolator® Synergy™ Ablation System, AtriClip® Left Atrial Appendage Exclusion System, Hybrid AF™ Therapy, cryoICE cryoSPHERE®+ and cryoSPHERE MAX™ probes, and cryoXT® probes, as well as other products like multifunctional pens and linear ablation devices.

AtriCure, Inc. is headquartered in Mason, Ohio, USA, with additional offices in Minneapolis and Pleasanton, USA, and Amsterdam, Netherlands. The company markets and sells its products to medical centers in the United States, the Asia-Pacific region, Germany, France, the UK, the Benelux region, Canada, and Australia. A majority of its revenue is generated from the United States, with additional revenue from international markets.

AtriCure has established itself as a leader in the field of surgical Afib ablation, achieving an estimated 60% market share. The company is committed to environmental, social, and governance (ESG) responsibilities, focusing on sustainability, patient care, employee empowerment, and partner collaboration. Its reputation is built on innovating devices that directly support patient care and recovery. AtriCure's Isolator® Synergy™ Ablation System is noted as the first medical device to receive FDA approval for persistent Afib, and its AtriClip® products are the most widely sold LAA management devices globally.

AtriCure's ownership is predominantly held by institutional investors, with approximately 81.46% of the company's stock held by them as of mid-2025. Major institutional shareholders include The Vanguard Group, Inc., BlackRock, Inc., and Wellington Management Group Llp. Insiders represent a smaller portion, accounting for approximately 3.55% as of mid-2025. The current President and CEO, Michael H. Carrel, holds a direct stake of 1.76% as of March 9, 2025. Public companies and individual investors account for the remaining portion, approximately 14.99% as of mid-2025.